Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 328

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease

Open access
Bhandari, Sunil, Mehta, Samir, Khwaja, Arif, Cleland, John G.F., Ives, Natalie, Brettell, Elizabeth, Chadburn, Marie, Cockwell, Paul·2022·New England Journal of Medicine

Abstract

BACKGROUNDRenin-angiotensin system (RAS) inhibitors -including angiotensin-convertingenzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) -slow the progression of mild or moderate chronic kidney disease.However, the results of some studies have suggested that the discontinuation of RAS inhibitors in patients with advanced chronic kidney disease may increase the estimated glomerular filtration rate (eGFR) or slow its decline. METHODSIn this multicenter, open-label trial, we randomly assigned patients with advanced and progressive chronic kidney disease (eGFR, <30 ml per minute per 1.73 m 2 of body-surface area) either to discontinue or to continue therapy with RAS inhibitors.The primary outcome was the eGFR at 3 years; eGFR values that were obtained after the initiation of renal-replacement therapy were excluded.Secondary outcomes included the development of end-stage kidney disease (ESKD); a composite of a decrease of more than 50% in the eGFR or the initiation of renal-replacement therapy, including ESKD; hospitalization; blood pressure; exercise capacity; and quality of life.Prespecified subgroups were defined according to age, eGFR, type of diabetes, mean arterial pressure, and proteinuria. RESULTSAt 3 years, among the 411 patients who were enrolled, the least-squares mean (±SE) eGFR was 12.6±0.7 ml per minute per 1.73 m 2 in the discontinuation group and 13.3±0.6ml per minute per 1.73 m 2 in the continuation group (difference, -0.7; 95% confidence interval [CI], -2.5 to 1.0; P = 0.42), with a negative value favoring the outcome in the continuation group.No heterogeneity in outcome according to the prespecified subgroups was observed.ESKD or the initiation of renalreplacement therapy occurred in 128 patients (62%) in the discontinuation group and in 115 patients (56%) in the continuation group (hazard ratio, 1.28; 95% CI, 0.99 to 1.65).Adverse events were similar in the discontinuation group and continuation group with respect to cardiovascular events (108 vs. 88) and deaths (20 vs. 22). CONCLUSIONSAmong patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decrease in the eGFR.(Funded by the National Institute for Health Research and the Medical Research Council; STOP ACEi EudraCT number, 2013 -003798 -82; ISRCTN number, 62869767.)a bs tr ac t Renin-Angiotensin System Inhibition in Advanced ChronicKidney Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2210639

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 328

Metadata

Authors
Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G. F., Ives, N., Brettell, E., Chadburn, M., & Cockwell, P.
Venue
New England Journal of Medicine
Published
2022-12
Volume
387
Issue
22
Pages
2021-2032
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4308054131
Cited by
328
References
23
FWCI
36.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease. https://app.cochat.ai/papers/10.1056/nejmoa2210639
The paper
Bhandari, S., Mehta, S., Khwaja, A., Cleland, J. G. F., Ives, N., Brettell, E., Chadburn, M., & Cockwell, P. (2022). Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2210639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.